522 Results

People

  1. De Angelis
    De Angelis
  2. Kris
    Kris
  3. Motzer
    Motzer
  4. Livingston
    Livingston
  5. Aghajanian
    Aghajanian
  6. Krown
    Krown
  7. Panageas
    Panageas
  8. Miller
    Miller
  9. Tyson
    Tyson
  10. Vickers
    Vickers

Groups

  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)
  7. Tow Center for Developmental Oncology (TCDO) (51)
  8. Epidemiology and Biostatistics (49)
  9. Population Sciences Research Program (45)
  10. Genitourinary Oncology Service (41)
  1. "headache"
Formats
  1. Journal Article (491)
  2. Review (17)
  3. Research Letter (5)
  4. Conference Paper (3)
  5. Editorial (3)
  6. Book Whole (1)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)

More Groups

People
  1. Lisa De Angelis (20)
  2. Mark Kris (20)
  3. Robert Motzer (19)
  4. Philip Livingston (13)
  5. Carol Aghajanian (12)
  6. Katherine Panageas (12)

More People

Years
  1. 2025 (15)
  2. 2024 (34)
  3. 2023 (30)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (23)
  3. Lancet Oncology (20)
  4. Blood (18)
  5. New England Journal of Medicine (17)
  6. Cancer (16)

More Publications

Publishers
  1. Elsevier Inc. (68)
  2. Elsevier Science, Inc. (43)
  3. Springer (42)
  4. American Society of Clinical Oncology (37)
  5. Nature Publishing Group (32)
  6. Oxford University Press (29)

More Publishers

Results (522)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies
    Journal Article

    Desai, P.; Lonial, S.; Cashen, A.; Kamdar, M.; Flinn, I.; O'Brien, S.; Garcia, J. S.; Korde, N.; Moslehi, J.; Wey, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study
    Journal Article

    Choueiri, T. K.; Albiges, L.; Barthélémy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P.; Basu, A.; Bourlon, M. T.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
    Journal Article

    Elias, A. D.; Staley, A. W.; Fornier, M.; Vidal, G. A.; Alami, V.; Sams, S.; Spoelstra, N. S.; Goodspeed, A.; Kabos, P.; Diamond, J. R.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: A two-arm pilot study evaluating clinical outcomes and immunological correlates
    Journal Article

    Jansen, C. S.; Pagadala, M. S.; Cardenas, M. A.; Prabhu, R. S.; Goyal, S.; Zhou, C.; Chappa, P.; Vo, B. T.; Ye, C.; Hopkins, B.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – A plain language summary
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
    Journal Article

    Cederquist, G. Y.; Schefflein, J.; Devlin, S. M.; Shah, G. L.; Shouval, R.; Hubbeling, H.; Tringale, K.; Tomas, A. A.; Fregonese, B.; Hajj, C.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • COLUMBIA-1: A randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
    Journal Article

    Segal, N. H.; Tie, J.; Kopetz, S.; Ducreux, M.; Chen, E.; Dienstmann, R.; Hollebecque, A.; Reilley, M. J.; Elez, E.; Cosaert, J.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Autonomic dysreflexia in patients with cancer and spinal cord injury: A case series
    Journal Article

    Qin, E.; Marshall, G. M.; Ruppert, L.
    Spinal Cord Series and Cases (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save